首页
400-620-6333
切换导航
搜索
基本描述
| 英文名称 | vibegron |
|---|---|
| 别名 | compound 7;Gemtesa,KRP-114V;MK-4618;MK4618 |
| 英文别名 | compound 7;Gemtesa,KRP-114V;MK-4618;MK4618 |
名称和标识符
| INCHI | InChI=1S/C26H28N4O3/c31-24-14-15-27-23-13-12-22(30(23)24)26(33)29-19-8-6-17(7-9-19)16-20-10-11-21(28-20)25(32)18-4-2-1-3-5-18/h1-9,14-15,20-22,25,28,32H,10-13,16H2,(H,29,33)/t20-,21+,22-,25+/m0/s1 |
|---|---|
| InChi Key | DJXRIQMCROIRCZ-XOEOCAAJSA-N |
| Canonical SMILES | O=C([C@@H]1CCc2n1c(=O)ccn2)Nc1ccc(cc1)C[C@@H]1CC[C@@H](N1)[C@@H](c1ccccc1)O |
| PubChem CID | 44472635 |
数据库链接
| PubChem CID | 44472635 |
|---|---|
| CAS Registry No. | 1190389-15-1 |
| ChEMBL Ligand | CHEMBL2107826 |
| BindingDB Ligand | 50146154 |
| Reactome Reaction | R-HSA-9611839 |
| Reactome Drug | R-ALL-9624761 |
| DrugCentral Ligand | 5311 |
| GPCRdb Ligand | vibegron |
关联配体
| Ligand ID | 10100 |
|---|---|
| 名称 | vibegron |
| 别名 | MK-4618 |
| 类别 | Synthetic organic |
| 学名 | 4-amino-N-(4,6-dimethylpyrimidin-2-yl)benzenesulfonamide |
| 生物活性评价 |
Vibegron is inactive at the β1 and β2 adrenoceptors |
| 评价 |
Vibegron (MK-4618) is a potent and selective β3 adrenoceptor agonist that was developed by Merck as a pharmacological modulator for the management of overactive bladder |
| 临床描述 |
This study is designed to evaluate the safety, tolerability, and efficacy of vibegron administered once daily in patients with OAB. This study is designed to evaluate the safety, tolerability, and efficacy of vibegron administered once daily in participants with OAB for up to 52 weeks. |
| 来源公司 |
Urovant Sciences GmbH Urovant Sciences GmbH |
产品问答
产品问答
参考文献
| 1. Di Salvo J, Nagabukuro H, Wickham LA, Abbadie C, DeMartino JA, Fitzmaurice A, Gichuru L, Kulick A, Donnelly MJ, Jochnowitz N et al.. (2017) Pharmacological Characterization of a Novel Beta 3 Adrenergic Agonist, Vibegron: Evaluation of Antimuscarinic Receptor Selectivity for Combination Therapy for Overactive Bladder.. J Pharmacol Exp Ther, 360 (2): (346-355). [PMID:27965369] |
| 2. Edmondson SD, Zhu C, Kar NF, Di Salvo J, Nagabukuro H, Sacre-Salem B, Dingley K, Berger R, Goble SD, Morriello G et al.. (2016) Discovery of Vibegron: A Potent and Selective β3 Adrenergic Receptor Agonist for the Treatment of Overactive Bladder.. J Med Chem, 59 (2): (609-23). [PMID:26709102] |
上海阿拉丁生化科技股份有限公司
? 2016 ALADDIN-E.COM . 版权所有,未经授权禁止拷贝本站资料,如有违反,将追究法律责任
危险品化学品经营许可证（带存储）